Key result
VEGFR-TKIs increase the risk of all-grade hypertensive events ~3.9-fold in cancer patients.
Why the study?
Do vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) increase the incidence and risk of all-grade and high-grade hypertensive events compared to control therapies in patients with cancer?
Meta-Analysis (n=30,013)
Randomized controlled trials
Do vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) increase the incidence and risk of all-grade and high-grade hypertensive events compared to control therapies in patients with cancer?
Cancer patients treated with VEGFR-TKIs face a nearly 4-fold increased risk of all-grade hypertension and a 4.6-fold increased risk of high-grade hypertension, underscoring the need for routine blood pressure monitoring and early antihypertensive intervention to prevent cardiovascular complications.
Answers are grounded in this paper and cite their sources.
Requires routine BP monitoring with VEGFR-TKI therapy; confirms and quantifies hypertension risk across cancer trials.
// Bo Liu 1,3 , Fengxia Ding 2,3 , Yang Liu 1,3 , Geng Xiong 1,4 , Tao Lin 1 , Dawei He 1 , Yuanyuan Zhang 4 , Deying Zhang 1,3 and Guanghui Wei 1 1 Department of Urology, Children’s Hospital of Chongqing Medical University, Chongqing, China 2 Department of Respiratory Medicine, Children’s Hospital of Chongqing Medical University, Chongqing, China 3 Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing International Science and Technology Cooperation Center for Child Development and Disorders, Chongqing, China 4 Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA Correspondence to: Deying Zhang, email: // Guanghui Wei, email: // Keywords : meta-analysis, cancer, VEGFR-TKIs, hypertensive events Received : April 28, 2016 Accepted : August 23, 2016 Published : September 01, 2016 Abstract Background: Tyrosine kinase inhibitors (TKIs) have been developed during the last decade that target the vascular endothelial growth factor receptor (VEGFR) are currently being evaluated as treatments for malignant tumors. The increased application of VEGFR-TKIs means that the probability of hypertension is a serious concern. However, the reported incidence varies markedly between clinical trials. Here, we undertook an up-to-date, comprehensive meta-analysis on clinical works to build the incidence of hypertension along with VEGFR-TKIs. The goal was to understand better of the overall venture of cancer patients’ hypertension treated with these drugs. Methods: Databases (EMBASE, PubMed, and Cochrane library) and the abstracts of the American Society of Clinical Oncology annual meeting and European Society of Medical Oncology were searched to identify related studies. 95% confidence intervals (CIs), summary incidences, and relative risk (RR) were calculated utilizing either fixed-effects models on the basis of the heterogeneity of the included studies or random-effects. Results: Seventy-two randomized controlled trials (including 30013 patients) were involved. The total incidence of high-grade and all-grade hypertensive events along with VEGFR-TKIs was 23.0% (95% CI, 20.1–26.0%) and 4.4% (95% CI, 3.7–5.0%), respectively. The use of VEGFR-TKIs remarkably enhanced the venture of developing high-grade (RR, 4.60; 95% CI, 3.92–5.40; P < 0.001) and all-grade (RR, 3.85; 95% CI, 3.37–4.40; P < 0.001) hypertensive events. Subgroup analyses revealed that the risk of a hypertensive event varied significantly in accordance with tumor type, VEGFR-TKI, trial phase, VEGFR-TKIs-based regimen, control therapy, and chemotherapy regimen. Conclusions: Patients with cancer that receive VEGFR-TKIs are at a remarkable venture of developing hypertension. Therefore, suitable treatment and monitoring should be introduced to avoid cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2016) conducted a meta-analysis in Malignant tumors / cancer (n=30,013). Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) vs. Control treatments (placebo, current chemotherapy, best supportive care, and standard of care) was evaluated on All-grade hypertensive events (recorded according to NCI CTCAE 2.0 or 3.0) (RR 3.85, 95% CI 3.37-4.40, p=<0.001). VEGFR-TKIs increased the risk of all-grade and high-grade hypertensive events in cancer patients.
Synapse has enriched 10 related papers. Consider them for comparative context: